On July 5th, 2024, Kangfang Biotech (Cayman) Limited submitted the latest monthly report of securities changes to the Hong Kong Exchanges and Clearing Limited, reporting on the company's share changes as of June 30, 2024. The report shows that the company's authorized/registered share capital and issued shares (excluding treasury shares) remained unchanged during the reporting period, maintained at 5,000,000,000 ordinary shares with a par value of 0.00001 US dollars per share, for a total of 50,000 US dollars; the total number of issued shares is 865,857,176 shares. In addition, the company's share option plan has no new changes this month, with 436,000 share options in inventory and 27,000 shares that may be issued or transferred from treasury stock. The company also confirms that all sales or...Show More

On July 5th, 2024, Kangfang Biotech (Cayman) Limited submitted the latest monthly report of securities changes to the Hong Kong Exchanges and Clearing Limited, reporting on the company's share changes as of June 30, 2024. The report shows that the company's authorized/registered share capital and issued shares (excluding treasury shares) remained unchanged during the reporting period, maintained at 5,000,000,000 ordinary shares with a par value of 0.00001 US dollars per share, for a total of 50,000 US dollars; the total number of issued shares is 865,857,176 shares. In addition, the company's share option plan has no new changes this month, with 436,000 share options in inventory and 27,000 shares that may be issued or transferred from treasury stock. The company also confirms that all sales or transfers of securities issued or held in treasury stock have been formally authorized and approved by the board of directors, and comply with all applicable listing rules, laws, and other regulatory requirements. The restricted share unit plan adopted on August 29, 2019, before the initial public offering, mentioned in the report was terminated on June 30, 2024.